Monograph
R03CC02 - Salbutamol |
Not porphyrinogenic |
NP |
Rationale
Rather low dose, in large parts excreted unmetabolized. No data pointing to CYP-interaction. Three references consider it safe. Occasional clinical observations of tolerance.
Chemical description
Adrenergic bronchodilator for systemic treatment (tabl. 2 - 4 mg, oral solution 0,4 mg/mL) of asthma, bronchitis and emphysema. Metabolized in the liver. About 35 % excreted in urine in unchanged form. Weak inhibitor of CYP 3A4. EPI-list: safe South African list: use French list: autorized Kauppinen and Mustajoki. Prognosis of acute porphyria... Medicine 1992; 71: 1-13: Reported to be tolerated (n=2) Used in porphyria ward (Sweden).
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Finland
Latvia
Serbia© NAPOS 2024